Categories: BioTechMedTech
AltruBio is a biopharma company developing new antibody therapeutics for the treatment of immunological diseases.
AltruBio has introduced an antibody that targets a novel regulator of the immune system to precisely remove chronically over-activated T-cells partly responsible for causing autoimmune disease.
AltruBio's approach balances the benefit of precisely targeting the immune system to reduce autoimmune diseases with avoiding overcorrecting the immune system. The method has displayed proof of mechanism in four autoimmune and inflammatory diseases.
AltruBio's pipeline includes programs aimed at combatting acute Graft Versus Host Disease, and Ulcerative Colitis.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.04.2021 | Series A | $63M | aMoon Fund |
Mentions in press and media 4
Reviews 0
